This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Deckers, Allscripts: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Deckers Outdoor (DECK) were getting hammered in late trades on Thursday after the fashion footwear seller missed Wall Street's consensus profit view because of weakness in gross margins and lowered its full-year outlook.

The Goleta, Calif.-based company, whose brands include UGG boots and Teva scandals, earned $8 million, or 20 cents a share, on sales of $246.3 million in the first quarter, below the average estimate of analysts polled by Thomson Reuters for a profit of 25 cents on revenue of $246.5 million.

For the second quarter, Deckers sees year-over-year revenue growth of 8%, a loss per share of 60 cents a share and gross margin of 43%, a sequential decline from 46% in the latest quarter. The company lowered its view for fiscal 2012 to a year-over-year decrease of 9-10% in earnings per share from a prior view for a flat performance.

The stock was last quoted at $56.91, down 18%, on volume of more than 400,000, according to

"Our first quarter performance was mixed versus our expectations," stated Angel Martinez, President, Chief Executive Officer and Chair of the Board of Directors. "Sales growth was driven by the addition of the Sanuk brand combined with increased demand for the UGG brand spring line, partially offset by softness in boots due to the unusually warm weather. The difference in the channel mix versus projections, along with some higher closeouts for the Teva brand and non-Classic UGG brand styles, put some additional pressure on overall gross margins on top of the higher product costs we had forecasted."

Deckers attributed its lower full-year outlook to the higher costs of goods sold and increasing levels of closeout sales.

Check out TheStreet's quote page for Deckers Outdoor for year-to-date share performance, analyst ratings, earnings estimates and much more.

Allscripts Health Solutions

Shares of Allscripts Health Solutions (MDRX - Get Report) plunged late Thursday after the company's first-quarter results fell far short of Wall Street expectations because of weak sales, elevated software development expenses and an unfavorable sales mix.

The company reported non-GAAP earnings of 12 cents a share on revenue of $365.5 million for the March quarter. The average estimate of analysts polled by Thomson Reuters was for earnings of 24 cents a share on revenue of $387.7 million.

Allscripts also lowered its outlook, announced that Chief Financial Officer Bill Davis is leaving the company, and disclosed a shake-up of its board with Phil Pead being terminated as chairman and three other directors resigning.

The stock dropped 46% to $8.70 on after-hours volume of 5.3 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMZN $659.75 9.60%
DECK $57.81 -0.65%
EXPE $115.74 8.20%
MDRX $13.41 -1.20%
SBUX $56.24 -0.32%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs